GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Hemophilia overview

Hemophilia, a bleeding disorder affecting blood clotting, leads to prolonged bleeding or oozing after injury, surgery, or minor trauma. Severe cases involve spontaneous bleeding, posing risks like joint, muscle, or internal organ bleeding. Hemophilia A (factor VIII deficiency) and hemophilia B (factor IX deficiency) are major types, caused by variants in the F8 or F9 genes. These variants affect the production of coagulation factors VIII or IX, crucial for blood clotting. Severe variants cause significant clotting impairment, while milder forms may not manifest until after surgery or injury. Acquired hemophilia, a rare form, is not inherited but results from autoantibodies attacking coagulation factor VIII, often associated with pregnancy, immune disorders, cancer, or drug reactions.

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

G lobalDat a, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.